1800 244 735

Helpline (02) 9874 9777

Caution urged for the use of gene-editing technology CRISPR

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three independent studies which each sought to edit a single gene have shown that other parts of the DNA were also unexpectedly changed.

These studies are presented in an unfinalized online format and are still working their way through the scientific peer review process before formal publication. This means that there may still be errors in the science presented in the manuscripts which have yet to be spotted. However, as these independent and parallel studies all corroborate the finding that CRISPR technology can have off-target effects, there has already been mainstream and scientific media attention to these results. Although CRISPR still holds much promise as a research tool, it seems it is still a way off from being ready to be used as a medicine.

CRISPR can be used to make permanent changes to our DNA

The CRISPR system was first discovered as a type of immune system used by bacteria to defend themselves against viruses and other invaders by chopping up foreign genetic material. There are two components to the CRISPR machinery: A special piece of genetic message called a guide RNA that finds and points to the invader’s DNA, and an enzyme that can cut the DNA to destroy it. Check out this previous HDBuzz article for a detailed look at how CRISPR works and the challenges faced by the researchers exploring it.

Scientists can manipulate the system by changing the guide RNA to a target sequence and can therefore use the CRISPR system to make edits at precise parts of the genome. These edits are permanent changes to the genome and will be passed down from one generation to the next. Since its discovery in the late 2000s, scientists have been dreaming up all sorts of ideas and uses for CRISPR. For example, could it be possible to edit out the HD gene expansion in embryos? These ideas are not without controversy given the ethical dilemmas surrounding genetic manipulation of humans or other species. CRISPR hit the headlines in 2018 when the CRISPR experiments of rogue scientist He Jiankui at the Southern University of Science and Technology in China resulted in the birth of twin girls who had their genomes edited.

A not so perfect system

The three recent studies were conducted by scientists at the Francis Crick Institute in London, Columbia University in New York City and Oregon Health & Science University in Portland. Each team of scientists used CRISPR to make different edits in human embryos donated to research. The three experiments targeted genes involved in fetus development, blindness and heart problems. All of the studies found that CRISPR gene editing could lead to very big and unintended changes to other parts of the genome, including large deletions and rearrangements in regions close to the target gene. This is bad because our DNA code is a very precise set of instructions, which can be thought of like a cooking recipe. If you rearranged the steps in a recipe or got rid of some of the ingredients the outcome would not be good!

These off-target effects are due to problems in repairing the DNA, although there is not consensus amongst the studies as to how that might be happening. One thing all of the scientists do agree on though is that this should give everyone pause for thought when considering using CRISPR for genome editing as the technology is not as fine-tuned as previously thought.

What does the future hold for CRISPR and HD?

The permanent nature of CRISPR-based therapies for genetic illnesses like HD is both attractive and daunting. In theory, CRISPR could be used to irreversibly cut out some of the CAG repeats in the expanded huntingtin gene within an embryo. That way, the person who grows from that embryo wouldn’t have HD and neither would their children. The permanent nature of edits made by CRISPR technology means that unintended consequences would not only affect the individual, but would also be passed from one generation to the next. Scientists are not keen to roll out the technology for these type of gene-therapies until they are absolutely certain that it is safe and working as planned.

The good news is that these recent discoveries have alerted scientists to the limitations of CRISPR technology. This will by no means stop scientists from dreaming big about how CRISPR could be useful in the future, but the community will move forward more cautiously. Scientists will now consider how best to improve the technology to avoid these types of problems and hopefully use CRISPR as a safe therapy for different genetic illnesses in the future.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more